A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

American Heart Journal

Volumn 161, Issue 2, 2011, Pages

  Povsic, Thomas J ^a   Cohen, Mauricio G ^b   Mehran, Roxana ^c   Buller, Christopher E ^d   Bode, Christoph ^e   Cornel, Jan H ^f   Kasprzak, Jarosław D ^g   Montalescot, Gilles ^h   Joseph, Diane ^a   Wargin, William A ⁱ   Rusconi, Christopher P ^j   Zelenkofske, Steven L ^k   Becker, Richard C ^a   Alexander, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d HAMILTON GENERAL HOSPITAL   (Canada)

^e TU BERGAKADEMIE FREIBERG   (Germany)

^f Location Alkmaar   (Netherlands)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ PK PM Associates LLC   (United States)

^j Regado Biosciences   (United States)

^k Regado Biosciences   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 9A; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RB 006; RB 007; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; HEART CATHETERIZATION; HEMOSTASIS; HUMAN; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 79851499067     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.10.022     Document Type: Article

References (36)

1. Harrington R.A., Becker R.C., and Cannon C.P. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 133 2008 670S 707S (Pubitemid 351892975)
2. Stone G.W., Witzenbichler B., and Guagliumi G. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230 (Pubitemid 351724451)
3. Rao S.V., O'Grady K., and Pieper K.S. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206 (Pubitemid 41505393)
4. Rao S.V., O'Grady K., and Pieper K.S. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes J Am Coll Cardiol 47 2006 809 816 (Pubitemid 43243106)
5. Rao S.V., Kaul P.R., and Liao L. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes Am Heart J 155 2008 369 374
6. Rao S.V., Jollis J.G., and Harrington R.A. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562 (Pubitemid 39314961)
7. Hirsh J., O'Donnell M., and Eikelboom J.W. Beyond unfractionated heparin and warfarin: current and future advances Circulation 116 2007 552 560 (Pubitemid 47450264)
8. Kimmel S., Sekeres M., and Berlin J. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting J Clin Epidemiol 51 1998 1 10 (Pubitemid 28026509)
9. Seifert H., Jobes D., and Ten Have T. Adverse events after protamine administration following cardiopulmonary bypass in infants and children Anesth Analg 97 2003 383 389 (Pubitemid 36899734)
10. Weiler J.M., Gellhaus M.A., and Carter J.G. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery J Allergy Clin Immunol 85 1990 713 719 (Pubitemid 20141135)
11. Collett J.P., Montalescot G., and Lison L. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris Circulation 103 2001 658 663 (Pubitemid 32144193)
12. Ferguson J.J., Califf R.M., and Antman E.M. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
13. Stone G.W., Ware J.H., and Bertrand M.E. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial JAMA 298 2007 2497 2506 (Pubitemid 350223536)
14. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
15. Kjalke M., Monroe D.M., and Hoffman M. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation Thromb Haemost 80 1998 578 584 (Pubitemid 28479342)
16. Mann K., Brummel K., and Butenas S. What is all that thrombin for? J Thromb Haemost 1 2003 1504 1514
17. Monroe D.M., Hoffman M., and Roberts H.R. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets Blood Coagul Fibrinolysis 7 1996 459 464 (Pubitemid 26291519)
18. Howard E.L., Becker K.C., and Rusconi C.P. Factor IXa inhibitors as novel anticoagulants Arterioscler Thromb Vasc Biol 27 2007 722 727 (Pubitemid 46606698)
19. Zelenkofske S.L., Rusconi C.P., and Damiento C.M. Subcutaneous RB006, a direct FIXa inhibitor, provides prolonged anticoagulation with rapid reversal: the first clinical experience with the REG2 system Poster presented at: Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Session Sessions; April 9, 2010; San Francisco, CA 2010
20. Rusconi C.P., Scardino E., and Layzer J. RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94 (Pubitemid 34987876)
21. Dyke C.K., Steinhubl S.R., and Kleiman N.S. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497 (Pubitemid 44901522)
22. Gold L., Polisky B., and Uhlenbeck O. Diversity of oligonucleotide functions Ann Rev Biochem 64 1995 763 797
23. Nimjee S.M., Rusconi C.P., and Sullenger B.A. APTAMERS An emerging class of therapeutics Ann Rev Med 56 2005 555 583
24. Chan M.Y., Cohen M.G., and Dyke C.K. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Circulation 117 2008 2865 2874 (Pubitemid 351787073)
25. Chan M.Y., Rusconi C.P., and Alexander J.H. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor J Thromb Haemost 6 2008 789 796 (Pubitemid 351524539)
26. Cohen M.G., Purdy D.A., and Rossi J.S. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention Circulation 122 2010 614 622
27. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195 (Pubitemid 350123680)
28. Stone G.W., Bertrand M., and Colombo A. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale Am Heart J 148 2004 764 775
29. Lincoff A.M., Kleiman N.S., and Kereiakes D.J. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial JAMA 292 2004 696 703 (Pubitemid 39062523)
30. Biancari F., D'Andrea V., and Di Marco C. Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty Am Heart J 159 2010 518 531
31. Vaitkus P.T. A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention J Invasive Cardiol 16 2004 243 246 (Pubitemid 38637895)
32. Koreny M., Riedmüller E., and Nikfardjam M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis JAMA 291 2004 350 357 (Pubitemid 38101608)
33. Sanborn T.A., Ebrahimi R., and Manoukian S.V. Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The ACUITY Trial Circ Cardiovasc Interv 3 2010 57 62
34. Marso J.P., Amin A.P., and House J.A. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention JAMA 303 2010 2156 2164
35. Dauerman H.L., Applegate R.J., and Cohen D.J. Vascular closure devices: the second decade J Am Coll Cardiol 50 2007 1617 1626 (Pubitemid 47562669)
36. Arora N., Matheny M.E., and Sepke C. A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices Am Heart J 153 2007 606 611 (Pubitemid 46440677)